Compare Biogen Inc (BIIB) vs Reddit Inc (RDDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Reddit Inc — how do they compare? Biogen Inc trades at $193.42 (market cap $28.34B), while Reddit Inc trades at $195.42 (market cap $39.13B). The key difference: Reddit Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, Reddit Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | RDDT | |
|---|---|---|
Market Cap | $28.34B | $39.13B |
Sector | Health | Media |
52-Week High | $216.63 | $270.71 |
52-Week Low | $122.68 | $121.84 |
Enterprise Value | $30.62B | $36.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Reddit (RDDT) trades at $200.71, up 2.71% today, with a bullish technical outlook supported by moving averages and ADX signals. The stock shows strong fundamentals with 45% revenue growth, a 28.6% net income margin, and robust cash flow. Recent news highlights AI safety initiatives and digital ad momentum, while Q2 2026 earnings are anticipated on July 30, 2026.
The investment outlook is positive, driven by earnings beats, analyst consensus of $235.25 price target, and 63% buy ratings. Risks include high valuation multiples and competitive pressures in digital advertising. Upside potential hinges on sustained user engagement and execution of growth strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Reddit Inc
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →
